Brind.
  1. Novartis acquired MorphoSys for $2.9B. Barbara Krebs-Pohl joined the CASI Board of Directors and previously served as CBO at MorphoSys.

Antibe Therapeutics and Morphosys are both companies operating in the pharmaceutical development sector.

2 reports, 1 independent Updated Jun 27
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Antibe Therapeutics and Morphosys are both companies operating in the pharmaceutical development sector.

Who's involved

What this event is mainly about
Antibe TherapeuticsMorphosys

Keep exploring

Part of

Novartis acquired MorphoSys for $2.9B. Barbara Krebs-Pohl joined the CASI Board of Directors and previously served as CBO at MorphoSys. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story